Spots Global Cancer Trial Database for newly diagnosed
Every month we try and update this database with for newly diagnosed cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery | NCT02391194 | Breast Cancer | AVB-620 | 18 Years - | Avelas Biosciences, Inc. | |
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | NCT04324840 | Glioblastoma | CC-90010 Temozolomide Radiotherapy | 18 Years - | Celgene | |
| Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT02997423 | Glioblastoma | 21 Years - | University of Iowa | ||
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT00916409 | Glioblastoma Mu... | NovoTTF-100A de... Temozolomide | 18 Years - | NovoCure Ltd. | |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) | NCT02955810 | Multiple Myelom... | Daratumumab Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 70 Years | National University of Ireland, Galway, Ireland | |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | NCT01263418 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, B-Cel... Lymphoma, Low-G... Lymphoma, Inter... | Ofatumumab | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | NCT05181501 | Multiple Myelom... | Fully human BCM... | 18 Years - 70 Years | Nanjing IASO Biotechnology Co., Ltd. | |
| Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | NCT00910897 | Multiple Myelom... | Velcade-Dexamet... Velcade-Thalido... | 18 Years - 65 Years | Intergroupe Francophone du Myelome | |
| A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer | NCT00587093 | Ovarian Cancer | CA 125 and CT s... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | NCT00362570 | Oligoastrocytom... Anaplastic Olig... | Temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma | NCT01335399 | Multiple Myelom... | Lenalidomide Dexamethasone Dexamethasone Dexamethasone Dexamethasone Elotuzumab (BMS... Elotuzumab (BMS... | 18 Years - | Bristol-Myers Squibb | |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | NCT06289673 | Acute Lymphobla... Lymphoblastic L... Mixed Phenotype... | Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes | NCT00600860 | Myelodysplastic... | No intervention... | 18 Years - | Radboud University Medical Center | |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | NCT06289673 | Acute Lymphobla... Lymphoblastic L... Mixed Phenotype... | Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model | NCT02904525 | Glioblastoma | 7 Tesla MRI, no... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | NCT05376111 | T-cell Acute Ly... Recruiting | Venetoclax, Aza... | 15 Years - | The First Affiliated Hospital of Soochow University | |
| A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | NCT04485949 | Glioblastoma | IGV-001 Cell Im... Placebo Standard of Car... SOC: Temozolomi... | 18 Years - 70 Years | Imvax | |
| Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | NCT00031590 | Brain Tumors Central Nervous... Medulloblastoma | Cisplatin Cyclophosphamid... Etoposide Lomustine Vincristine Craniospinal Ra... | 3 Years - 30 Years | Children's Hospital of Philadelphia | |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | NCT00130195 | Acute Lymphobla... | imatinib cyclophosphamid... daunorubicin vincristine prednisolone methotrexate cytarabine dexamethasone | 15 Years - 64 Years | Japan Adult Leukemia Study Group | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | NCT03970447 | Glioblastoma | Temozolomide Lomustine Regorafenib Radiation Paxalisib VAL-083 VT1021 Troriluzole ADI-PEG 20 | 18 Years - | Global Coalition for Adaptive Research | |
| A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma | NCT05074992 | Glioblastoma | Ipilimumab | 18 Years - | University College, London | |
| A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | NCT01667536 | Prostate Cancer | Drug: 99mTc-MIP... | 21 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Sulindac for Patients With AML | NCT01843179 | Acute Myeloid L... | Cytarabine Sulindac | 60 Years - | Massachusetts General Hospital | |
| Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients | NCT00774839 | Colon Cancer | Patient Intervi... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients | NCT00774839 | Colon Cancer | Patient Intervi... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| cMet CAR RNA T Cells Targeting Breast Cancer | NCT01837602 | Metastatic Brea... Triple Negative... | cMet RNA CAR T ... | 18 Years - | University of Pennsylvania | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | NCT02507583 | Malignant Gliom... Neoplasms | IGF-1R/AS ODN; ... | 18 Years - | Thomas Jefferson University | |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | NCT01661881 | Mantle Cell Lym... | Rituximab Bendamustine Cytarabine | 18 Years - 69 Years | Dana-Farber Cancer Institute | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | NCT04740203 | B-Cell Acute Ly... | CAR-T cells tar... | 15 Years - | Zhejiang University | |
| 68Ga-PSMA-11 PET in Patients With Prostate Cancer | NCT05197257 | Prostate Cancer Prostate Adenoc... | Ga-PSMA-11 | 18 Years - 100 Years | University of Colorado, Denver | |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | NCT01661881 | Mantle Cell Lym... | Rituximab Bendamustine Cytarabine | 18 Years - 69 Years | Dana-Farber Cancer Institute | |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL | NCT04554459 | Acute Lymphobla... Ph+ ALL Newly Diagnosed | Ponatinib 15 MG... | 18 Years - 99 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | NCT03236792 | AL Amyloidosis | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients | NCT01506427 | Head and Neck C... | [F-18] HX4 | - | Siemens Molecular Imaging | |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL | NCT04554459 | Acute Lymphobla... Ph+ ALL Newly Diagnosed | Ponatinib 15 MG... | 18 Years - 99 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) | NCT00131053 | Lymphoblastic L... | Methotrexate Prednisolone Dexamethasone Vincristine Pirarubicin Cyclophosphamid... L-asparaginase Cytarabine Hydrocortisone Mercaptopurine | 15 Years - 24 Years | Japan Adult Leukemia Study Group | |
| A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | NCT01667536 | Prostate Cancer | Drug: 99mTc-MIP... | 21 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | NCT03641456 | Myeloma Newly Diagnosed High Risk | bortezomib Lenalidomide Dexamethasone | 18 Years - 75 Years | Sun Yat-sen University | |
| Circulating miRNAs. | NCT01722851 | Breast Cancer Newly Diagnosed... Recurrent Breas... | 18 Years - | Cancer Trials Ireland | ||
| Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | NCT04254640 | Acute Myeloid L... Elderly Patient... Newly Diagnosed | Cladribine Inje... Aclarubicin G-CSF cytarabine | 18 Years - 90 Years | Sun Yat-sen University | |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT04849715 | Mantle Cell Lym... | parsaclisib rituximab bendamustine Placebo | 18 Years - | Incyte Corporation | |
| Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | NCT04740203 | B-Cell Acute Ly... | CAR-T cells tar... | 15 Years - | Zhejiang University | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma | NCT00570180 | Multiple Myelom... | Bortezomib | 18 Years - | University Health Network, Toronto | |
| Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) | NCT01971658 | Multiple Myelom... | Thalidomide® Cyclophosphamid... Velcade® Dexaméthasone | 18 Years - 65 Years | Nantes University Hospital | |
| Alisertib for Acute Myeloid Leukemia | NCT01779843 | Acute Myelogeno... | Cytarabine Idarubicin Alisertib | 18 Years - | Massachusetts General Hospital | |
| Sulindac for Patients With AML | NCT01843179 | Acute Myeloid L... | Cytarabine Sulindac | 60 Years - | Massachusetts General Hospital | |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | NCT06409702 | Newly Diagnosed High Risk MRD Multiple Myelom... | Carfilzomib Daratumumab Lenalidomide Dexamethasone VRD for first-c... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761 | Leukemia, Myelo... De Novo Age More 60yr | Azacitidine Venetoclax Quizartinib Cytarabine Venetoclax Quizartinib | 60 Years - | PETHEMA Foundation | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | NCT00910897 | Multiple Myelom... | Velcade-Dexamet... Velcade-Thalido... | 18 Years - 65 Years | Intergroupe Francophone du Myelome | |
| Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients | NCT01346787 | Multiple Myelom... | CARFILZOMIB, CY... | 65 Years - | Stichting European Myeloma Network | |
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | NCT04324840 | Glioblastoma | CC-90010 Temozolomide Radiotherapy | 18 Years - | Celgene | |
| Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01829503 | Acute Myeloid L... | decitabine and ... Supportive Care | 60 Years - | University of Pittsburgh | |
| Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | NCT00031590 | Brain Tumors Central Nervous... Medulloblastoma | Cisplatin Cyclophosphamid... Etoposide Lomustine Vincristine Craniospinal Ra... | 3 Years - 30 Years | Children's Hospital of Philadelphia | |
| Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma | NCT03224104 | Astrocytoma, Gr... Glioblastoma | TG02 Radiation Thera... Temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma | NCT03224104 | Astrocytoma, Gr... Glioblastoma | TG02 Radiation Thera... Temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers | NCT02440737 | Cancer | Educational Int... Follow-Up Care Psychosocial As... Questionnaire A... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT02997423 | Glioblastoma | 21 Years - | University of Iowa | ||
| An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | NCT03606577 | Multiple Myelom... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma | NCT00782756 | Brain Cancer Malignant Gliom... | radiotherapy (R... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | NCT04573140 | Adult Glioblast... | Autologous tota... | 21 Years - | University of Florida | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL | NCT05287984 | Chronic Lymphoc... Small Lymphocyt... Newly Diagnosed | Zanubrutinib, F... Zanubrutinib, b... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | NCT04288765 | Multiple Myelom... | Daratumumab Onl... | 18 Years - 65 Years | Grupo Cooperativo de Hemopatías Malignas | |
| Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas | NCT01663090 | Soft Tissue Sar... | Ferumoxytol | 12 Years - | Dana-Farber Cancer Institute | |
| Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma | NCT01335399 | Multiple Myelom... | Lenalidomide Dexamethasone Dexamethasone Dexamethasone Dexamethasone Elotuzumab (BMS... Elotuzumab (BMS... | 18 Years - | Bristol-Myers Squibb | |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | NCT00130195 | Acute Lymphobla... | imatinib cyclophosphamid... daunorubicin vincristine prednisolone methotrexate cytarabine dexamethasone | 15 Years - 64 Years | Japan Adult Leukemia Study Group | |
| A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | NCT04573140 | Adult Glioblast... | Autologous tota... | 21 Years - | University of Florida | |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | NCT03236792 | AL Amyloidosis | Ixazomib Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
